| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | D-PLEX 100 prevention of surgical site infections in patients undergoing abdominal colorectal surgery BreakthroughPriority | PDUFA | — | Subscribe to access the data. | Nanomedicine | Infectious Diseases | |
PDUFA Date example | D-PLEX 100 prevention of surgical site infections in patients undergoing abdominal colorectal surgery BreakthroughPriority | PDUFA | — | Subscribe to access the data. | Nanomedicine | Infectious Diseases | |
PDUFA Date example | D-PLEX 100 prevention of surgical site infections in patients undergoing abdominal colorectal surgery BreakthroughPriority | PDUFA | — | Subscribe to access the data. | Nanomedicine | Infectious Diseases |
Recent Updates
Recently added Catalysts
PolyPid Ltd.
$4.99
-0.11 (-2.25%)
D 29Pipeline Score Richly Valued Biotech · Clinical
Market Cap
95.13 M
EPS
-1.91
P/E Ratio
-
Value Trade
1.63 M
5.39 %
Week
25.25 %
1 Month
3 %
3 Month
17.29 %
6 Month
-98.24 %
5 Year
-98.96 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
124.42 K
52 Week Range
3.06 - 5.73
% held by Insiders
63.91 %
% held by Institutions
18.17 %
Enterprise Value
87.04 M
Total Shares
19.10 M
Short %
5.99 %
Float Shares
11.23 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-03-31 | D-PLEX100 | NDA Filing | NDA | — | – | – | – |
2026-03-31 | D-PLEX100 | NDA Filing | NDA | — | – | – | – |
2026-03-31 | D-PLEX100 | NDA Filing | NDA | — | – | – | – |
Drug Pipeline Intelligence
D29
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 34%
Micro Cap (rank 617 of 933)
Percentile RankPolyPid Ltd. faces pipeline headwinds (29/100), with $98M risk-adjusted pipeline value, led by D-PLEX in Abdominal Surgery (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D-PLEX Small molecule | Surgical Site Infection | Phase 3 | NCT04411199 | 87% | $98M | COMPLETED | 1,952 | - | - | May 10, 2025 | - | MEDIUM Aug 13, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
D-PLEX₁₀₀ BreakthroughPriority | prevention of surgical site infections | Phase 3 | 2026-05-20 | successfully met its primary and all key secondary endpoints | PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference Read More | |
D-PLEX₁₀₀ BreakthroughPriority | prevention of surgical site infections | Phase 3 | 2026-05-20 | successfully met its primary and all key secondary endpoints | PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference Read More | |
D-PLEX₁₀₀ BreakthroughPriority | prevention of surgical site infections | Phase 3 | 2026-05-20 | successfully met its primary and all key secondary endpoints | PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PYPD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PYPD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PYPDPolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PolyPid has provided a corporate update highlighting the FDA's acceptance of its D-PLEX180 NDA with a priority review status. The PDUFA goal date is now set for November 28, 2026, which is approximately one quarter earlier than previously expected. Additionally, the company has secured a commercialization partnership with Azurity Pharmaceuticals, achieving $30 million in upfront and near-term milestones.
Read more →PYPD▲ +7.1%on this news
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PolyPid Ltd. will announce its second quarter 2026 financial results and operational highlights on August 12, 2026. The company will host a conference call and webcast at 8:30 AM ET to discuss these results. PolyPid is focused on developing long-acting, controlled-release drugs to enhance treatment effectiveness.
Read more →PYPD▲ +8.8%on this newsshared move
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
PolyPid Ltd. announced that the FDA has accepted its New Drug Application (NDA) for D-PLEX 100, granting it Priority Review for preventing surgical site infections in colorectal surgery. The FDA's acceptance, which identified no filing review issues, sets a PDUFA target action date of November 28, 2026. This milestone triggers a $15 million payment from Azurity Pharmaceuticals, completing a total of $30 million in upfront and milestone payments under their partnership.
Read more →PYPD▼ -27.4%on this news
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
PolyPid has entered an exclusive partnership with Azurity Pharmaceuticals for the commercialization of D-PLEX100 in the U.S. and Canada, aimed at preventing surgical site infections. The agreement includes an upfront payment of $15 million and potential milestone payments exceeding $300 million. The U.S. launch is targeted for Q1 2027, following positive Phase 3 trial results.
Read more →PYPDNOTICE FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON JULY 15, 2026 E XHIBIT 99.1 polypid Ltd. Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on
PolyPid Ltd. has announced that it will hold its Annual and Extraordinary General Meeting on July 15, 2026, at 2:00 p.m. Israel time. The meeting will take place at the company's office in Petach Tikva, Israel, and shareholders of record as of June 15, 2026, are eligible to vote. Detailed instructions regarding proxy voting and attendance have been provided to ensure shareholder participation.
Read more →PYPD▲ +7.4%on this news
PolyPid Completes New Drug Application Submission to FDA for D-PLEX 100 If approved, D-PLEX 100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently
PolyPid Ltd. has completed its New Drug Application submission to the FDA for D-PLEX100, aimed at preventing surgical site infections particularly in colorectal surgeries. The application follows the positive results from the pivotal Phase 3 SHIELD II trial, which met all primary and secondary endpoints, showing significant efficacy. The company is expecting a potential FDA approval decision in the first quarter of 2027, having received several expedited review designations from the FDA.
Read more →PYPDPolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PolyPid Ltd. will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026. The event will take place at the Depot Renaissance Hotel in Minneapolis, MN, where the company's management will hold investor meetings. PolyPid is recognized for developing innovative long-acting drugs aimed at enhancing treatment effectiveness.
Read more →PYPD▼ -7.5%on this news
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
PolyPid Ltd. has initiated the NDA submission for its lead product D-PLEX1800 aimed at preventing surgical site infections. The company is in the late stages of discussions for a U.S. commercial partnership and has presented positive Phase 3 data at medical congresses. Financially, the company reported a net loss of $7.7 million for Q1 2026, with sufficient cash resources to support operations into the second half of the year.
Read more →PYPDPolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PolyPid Ltd. will announce its first quarter 2026 financial results and operational highlights on May 13, 2026. The company will host a conference call and webcast at 8:30 AM ET to discuss these results and provide updates on its business operations. PolyPid focuses on developing innovative long-acting drugs for various medical needs.
Read more →PYPDPolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
PolyPid Ltd. announced it will present data from its Phase 3 SHIELD II trial at the Surgical Infection Society's annual meeting. The analysis shows a significant reduction in the severity of surgical site infections (SSIs) following colorectal surgery when using D-PLEX100. This could lead to better patient outcomes and reduced hospital resource use. The presentation will be led by Dr. Robert G. Sawyer.
Read more →PYPDPolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
PolyPid Ltd. will present new pharmacokinetic data from the Phase 3 SHIELD II trial for D-PLEX100 at the ESCMID Global 2026. The data indicates that D-PLEX100 can deliver doxycycline continuously for 30 days at the surgical site, significantly reducing the risk of surgical site infections. This innovative approach addresses a key limitation of conventional antibiotics.
Read more →PYPDPolyPid Initiates D-PLEX NDA Submission to the FDA PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track
PolyPid Ltd. has initiated the NDA submission for its lead product D-PLEX100 to the FDA for preventing surgical site infections in colorectal surgery patients. This submission is part of a rolling review process under the Fast Track designation, with the completion expected in the second quarter of 2026. The company reported positive results from the Phase 3 SHIELD II trial and is focusing on potential commercialization partnerships. The product aims to deliver a prolonged antibiotic effect at the surgical site using its innovative delivery technology.
Read more →PYPDPolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
PolyPid Ltd. announced that the FDA has granted a $4.3 million PDUFA fee waiver for its New Drug Application (NDA) for D-PLEX100, aimed at preventing surgical site infections. This waiver supports the company's upcoming NDA submission, following positive results from the Phase 3 SHIELD II trial, which demonstrated a 60% reduction in infection risk. PolyPid is also in discussions for commercial partnerships in the U.S.
Read more →PYPDPolyPid Announces Participation in Upcoming Investor Conferences
PolyPid Ltd. has announced its participation in two upcoming investor conferences in March 2026. The conferences include the Citizens 2026 Life Sciences Conference and the 38th Annual ROTH Conference, where investors can schedule one-on-one meetings with senior management. The company focuses on developing long-acting, controlled-release drugs to enhance treatment effectiveness.
Read more →PYPDPolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
PolyPid Ltd. has provided a corporate update and reported its financial results for 2025. The company successfully completed the SHIELD II Phase 3 trial for its lead product, D-PLEX 1800, and is in advanced discussions for U.S. commercial partnerships. Positive feedback from the FDA supports a rolling NDA review, with submission expected by the end of Q1 2026. The CEO expressed optimism for 2026 as a pivotal year for the company's transition to commercialization.
Read more →PYPDPolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
PolyPid Ltd. will report its fourth quarter 2025 financial results and operational highlights on February 11, 2026, before U.S. markets open. The company will host a conference call at 8:30 AM ET to discuss these results. PolyPid's lead product, D-PLEX100, is expected to have an NDA submission in early 2026 following positive phase 3 results.
Read more →PYPDpolypid Ltd. Notice of EXTRAORDINARY General Meeting of shareholders to be held on FEBRUARY 4, 2026 Notice is hereby given that an Extraordinary General Meeting of Shareholders (the " Meeting ") of PolyPid Ltd. (" PolyPi
PolyPid Ltd. has announced an Extraordinary General Meeting of shareholders scheduled for February 4, 2026, at its office in Petach Tikva, Israel. The meeting is intended for shareholders to discuss and vote on proposed resolutions supported by the Board of Directors. Shareholders of record as of January 5, 2026, are eligible to vote and may do so in person or by appointing proxies. The company emphasizes the importance of shareholder participation and outlines procedures for proxy voting.
Read more →PYPDPolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX 100 New Drug Application Submis
PolyPid has appointed Brooke Story as the Chairman of the Board of Directors, effective December 11, 2025. Her leadership is anticipated to enhance the company's strategic, commercial, and transaction capabilities, particularly as they prepare for the New Drug Application submission for D-PLEX100. Story brings over 25 years of experience in MedTech, which is expected to play a pivotal role in the commercialization of PolyPid's surgical solutions. The company is focused on addressing critical needs in surgical infection prevention with its innovative PLEX technology.
Read more →PYPDPolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX 100 Supporting NDA Submission NDA to be Submitted on a Rolling Basis, Beginning Early 2026
PolyPid Ltd. has received positive feedback from the FDA regarding its D-PLEX100 pre-New Drug Application (NDA) meeting. The FDA indicated that the existing clinical data is sufficient to support an NDA submission, which PolyPid plans to begin on a rolling basis in early 2026. D-PLEX100, designed to prevent surgical site infections following colorectal surgeries, recently demonstrated significant efficacy in the Phase 3 SHIELD II trial. The company’s Breakthrough Therapy designation further supports its development strategy and objectives.
Read more →PYPDPolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
PolyPid Ltd. announced its participation in a virtual KOL event on December 10, 2025, hosted by ROTH Capital Partners, where Dr. Steven D. Wexner will discuss the clinical impact of surgical site infections and the role of D-PLEX100 in addressing this issue. D-PLEX100 has shown promising results in reducing surgical site infections, having received FDA Breakthrough Therapy designation. The event will include a live Q&A session with PolyPid's management team, highlighting the firm’s ongoing efforts in improving surgical outcomes with its innovative therapies.
Read more →PYPDPolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
PolyPid Ltd. has provided a corporate update highlighting significant progress towards the NDA submission for D-PLEX100, expected in early 2026. The company is preparing for a pre-NDA meeting with the FDA in December and has engaged in discussions with potential U.S. partners following positive Phase 3 trial results. Additionally, PolyPid has successfully completed a GMP inspection, indicating readiness for commercial manufacturing.
Read more →PYPDPolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
PolyPid Ltd. announced that its lead candidate, D-PLEX™1800, has won the 'Therapeutics Solution of the Year' award from BioTech Breakthrough. This innovative product aims to prevent surgical site infections (SSIs) through localized antibiotic delivery. The recent Phase 3 SHIELD II trial showed a significant 58% reduction in SSIs, highlighting its potential impact on surgical care.
Read more →PYPDPolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
PolyPid Ltd. has announced the date for its third quarter 2025 financial results, which will be disclosed before U.S. market opening on November 12, 2025. The company will host a conference call and webcast to discuss these results and provide operational updates. Notably, PolyPid is on track to submit a New Drug Application for its lead product, D-PLEX100, which aims to prevent surgical site infections. The firm is positioned as a late-stage biopharma company with a focus on improving surgical outcomes through advanced therapeutics.
Read more →PYPDPolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
PolyPid Ltd. announced that Dr. Shmuel Sharoni will present the positive topline results from the Phase 3 SHIELD II trial of D-PLEX™1800 at the 2025 American College of Surgeons Clinical Congress. The trial demonstrated a significant reduction in surgical site infections and related complications. The company plans to submit a New Drug Application for D-PLEX™1800 in early 2026.
Read more →PYPDPolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
PolyPid Ltd. will present at the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, and participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. The company aims to improve surgical outcomes with its proprietary PLEX technology. Following positive phase 3 results, an NDA submission for its lead product candidate is anticipated in early 2026.
Read more →PYPDPolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
PolyPid Ltd. has successfully completed a Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health, marking the fourth consecutive successful inspection. This achievement confirms the company's manufacturing facility meets EU GMP compliance standards, paving the way for commercial production of its lead product candidate, D-PLEX1800. The company plans to submit a New Drug Application in early 2026, following positive Phase 3 trial results.
Read more →PYPDPolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
PolyPid Ltd. has announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference scheduled for September 8-9, 2025. Senior management will engage in a fireside chat and hold one-on-one meetings with investors. The company aims to improve surgical outcomes with its innovative PLEX technology and plans to submit a New Drug Application for its lead product candidate in early 2026.
Read more →PYPDPolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
PolyPid Ltd. announced that Deputy CEO Dalit Hazan will present at the 14th ICRS Conference from September 7-9, 2025. The presentation will focus on their PLEX technology and its successful Phase III trial. The company aims to improve surgical outcomes with its innovative drug delivery system, with an NDA submission for D-PLEX100 anticipated in early 2026.
Read more →PYPDPOLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Condensed Consolidated Balance Sheets 2 - 3 Interim Condens
Polypid Ltd. released its interim condensed consolidated financial statements for the period ending June 30, 2025, showing a substantial increase in total assets to $37,687 thousand from $25,220 thousand at the end of 2024. The company faced a net loss of $18,245 thousand during the six-month period, which is an increase compared to the previous year's loss of $12,742 thousand. Key highlights include an increase in cash and cash equivalents, as well as substantial financing from the issuance of ordinary shares. However, both the operating loss and accumulated deficit have shown significant growth, indicating a challenging financial landscape for the company.
Read more →PYPDPolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results Positive Phase 3 SHIELD II Trial Results - D-PLEX successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI;
PolyPid Ltd. has provided a corporate update alongside its financial results for Q2 2025, highlighting a successful Phase 3 SHIELD II trial for D-PLEX, which achieved a 58% reduction in surgical site infections. With an NDA submission anticipated for Q1 2026, the company also introduced a new delivery platform for GLP-1 receptor agonists targeting obesity and diabetes. Despite a strengthened balance sheet, PolyPid reported a substantial net loss during the quarter.
Read more →PYPD▲ +5.9%on this newsshared move
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
PolyPid Ltd. has appointed Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025. Dr. Tweezer-Zaks, who has been on the Board since November 2023, will bring her extensive medical expertise to lead the company's medical strategy. This appointment follows positive results from the Phase 3 SHIELD II trial and is aimed at advancing PolyPid's pipeline and preparing for a New Drug Application submission.
Read more →PYPDPolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
PolyPid Ltd. announced it will report its financial results for the second quarter of 2025 on August 13, 2025, before the U.S. market opens. Alongside the financial results, the company plans to provide operational highlights and updates during a scheduled conference call. PolyPid is advancing its lead candidate D-PLEX100, aimed at preventing surgical site infections, with a New Drug Application expected to be submitted in early 2026. The company continues to innovate with a pipeline in oncology, obesity, and diabetes.
Read more →PYPDPolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to sub
PolyPid Ltd. has unveiled a new long-acting GLP-1 receptor agonists delivery platform that aims to provide subcutaneous GLP-1 release for about 60 days. This innovation could significantly enhance patient care in diabetes and weight management by reducing the frequency of injections from weekly to a single dose. The technology has been clinically validated in over 1,000 patients and aims to tap into a rapidly growing market projected to reach $100 billion by 2030. Following positive Phase 3 results from its lead product candidate D-PLEX100, an NDA submission is expected in early 2026.
Read more →PYPDCompensation Policy PolyPid Ltd. (the "Company") Compensation Policy for Officers and Directors of the Company Table of Contents 1. Background 1 2. Compensation Objectives 1 3. Compensation policy 2 3.1. Officers' Compen
PolyPid Ltd. has proposed a comprehensive Compensation Policy detailing the compensation strategy for its officers and directors. The policy aims to align the interests of the officers with those of the company and its stakeholders, ensuring adherence to legal requirements. It outlines a mix of fixed and variable compensation components while enabling the company to attract and retain skilled personnel. The policy will be in effect for five years, requiring shareholder approval every three years thereafter.
Read more →PYPD▲ +7.6%on this news
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated
PolyPid has announced the successful exercise of warrants, raising $26.7 million following encouraging topline results from its SHIELD II Phase 3 trial. This funding is expected to extend the company's operational runway beyond the anticipated FDA approval of its lead product candidate, D-PLEX100, which aims to prevent surgical site infections (SSIs). The transaction closes around June 18, 2025, and proceeds will support PolyPid's NDA submission and other corporate purposes. D-PLEX100 has already received Breakthrough Therapy designation from the FDA.
Read more →PYPDPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX 100 Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints D-PLEX 100 s
PolyPid announced positive topline results from its Phase 3 SHIELD II trial, showcasing D-PLEX100's effectiveness in reducing surgical site infections in colorectal surgeries. The trial met its primary and all key secondary endpoints, indicating significant clinical benefits. Given the high rate of surgical site infections in this patient group, D-PLEX100 could provide a valuable addition to current surgical care practices. The company plans to submit a New Drug Application in early 2026, aiming for broader market impact with its innovative therapeutic approach.
Read more →PYPDPolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PolyPid Ltd. will host a conference call and webcast on June 9, 2025, to discuss topline results from its SHIELD II Phase 3 trial of D-PLEX100. This trial aims to evaluate the efficacy of D-PLEX100 in preventing surgical site infections among patients undergoing abdominal colorectal surgery. The company's proprietary PLEX technology is designed to optimize drug delivery, enhancing surgical recovery. PolyPid is also exploring other therapeutic possibilities for solid tumors, starting with glioblastoma.
Read more →PYPDPOLYPID LTD. AMENDED AND RESTATED 2012 SHARE OPTION PLAN 1. Definitions As used herein capitalized terms shall have the meanings set forth in Annex A hereto, unless the context clearly indicates to the contrary. 2. The P
Polypid Ltd. has amended and restated its 2012 Share Option Plan to enhance employee engagement through proprietary interest acquisition. The plan aims to incentivize employees, officers, and service providers by granting options that can lead to equity in the company. It establishes a structure for option grants, including vesting schedules and eligibility criteria, while reserving a specific number of shares for these options. This amendment reflects the company's strategy to attract and retain skilled personnel by aligning their interests with the company's performance.
Read more →PYPDpolypid Ltd. Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on
PolyPid Ltd. has announced an Annual and Extraordinary General Meeting of Shareholders scheduled for June 25, 2025. The meeting will take place at the company's office in Petach Tikva, Israel, at 2:00 p.m. local time. Shareholders of record as of May 27, 2025, are entitled to vote at the meeting, either in person or by appointing proxies. The Board of Directors recommends voting in favor of the proposed resolutions detailed in the attached proxy statement, emphasizing shareholder participation.
Read more →PYPDPolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
PolyPid Ltd. is set to participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The event will feature a webcast presentation by the company, as well as the opportunity for one-on-one meetings with management. PolyPid is focusing on improving surgical outcomes through its proprietary PLEX technology and is advancing its lead candidate, D-PLEX100, to Phase 3 clinical trials for preventing surgical site infections.
Read more →PYPD▲ +7%on this news
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX , with Top-Line Results Anticipated in Current Quarter Com
PolyPid Ltd. has provided an update regarding its corporate activities and reported its financial results for Q1 2025. The company has successfully completed enrollment in its Phase 3 SHIELD II trial for D-PLEX100, aimed at preventing surgical site infections. Top-line results from the trial are expected within the current quarter, while efforts to prepare for regulatory submissions and commercial launch are actively ongoing. PolyPid's CEO emphasized the study's strong design, enhancing confidence in the trial’s success probability.
Read more →PYPDPolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
PolyPid Ltd. will report its first quarter 2025 financial results and highlight operational updates on May 14, 2025, prior to the U.S. market opening. The late-stage biopharma company is focused on improving surgical outcomes with its proprietary PLEX technology. The company is currently progressing in its Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections, and is exploring further development of OncoPLEX for solid tumors. A conference call and webcast will follow the announcement to discuss the results and company operations.
Read more →PYPDPolyPid to Participate in The Citizens Life Sciences Conference
PolyPid Ltd. has announced its participation in The Citizens Life Sciences Conference scheduled for May 7-8, 2025, in New York. The management team will partake in a fireside chat as well as host one-on-one investor meetings. PolyPid focuses on improving surgical outcomes with its proprietary PLEX technology and has its lead product, D-PLEX100, in a Phase 3 clinical trial for preventing surgical site infections. The company also aims to advance OncoPLEX for treating solid tumors, starting with glioblastoma.
Read more →PYPDPolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Last Patient Enrolled Following Positive Recommendation b
PolyPid has announced the successful completion of enrollment in the Phase 3 SHIELD II trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgeries. This conclusion follows a favorable recommendation from the Data Safety Monitoring Board after reviewing data from the first 430 patients. The company expects to report top-line results by the end of Q2 2025 and plans to submit a New Drug Application to the FDA if these results are positive, leveraging Fast-Track and Breakthrough Therapy designations.
Read more →PYPD▼ -8.3%on this news
PolyPid to Participate in the 37th Annual ROTH Conference
PolyPid Ltd. will participate in the 37th Annual ROTH Conference from March 17-18, 2025, in Dana Point, California. The company's management will present and take part in one-on-one investor meetings, aiming to enhance investor engagement. PolyPid's focus on its PLEX technology and development of D-PLEX100 for preventing surgical site infections has positioned it as a notable player in improving surgical outcomes.
Read more →PYPDPolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients SHIELD II Enro
PolyPid Ltd. reported a positive corporate update along with financial results for Q4 and full year 2024. The company received a favorable recommendation from the Data Safety Monitoring Board to continue enrolling in the Phase 3 SHIELD II trial of its product D-PLEX100, which aims to prevent surgical site infections. Enrollment is currently over 700 patients and is expected to complete by March 2025, with top-line results anticipated in Q2 2025. PolyPid has also completed a private placement, bolstering its financial position to support upcoming regulatory submissions and operational needs.
Read more →PYPDPolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PolyPid Ltd. has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which will take place virtually from February 11 to 12, 2025. The company's management will present on-demand starting February 12, and they will also engage in one-on-one investor meetings during the event. PolyPid is focused on improving surgical outcomes with its PLEX technology and has ongoing clinical trials for its product candidate, D-PLEX100. Additionally, the company is exploring treatment options for solid tumors.
Read more →PYPDPolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
PolyPid Ltd. will announce its fourth quarter and full-year 2024 financial results on February 12, 2025. The company plans to host a conference call at 8:30 AM ET to discuss the results and provide business updates. PolyPid is a late-stage biopharma firm focused on improving surgical outcomes with its proprietary PLEX technology, which facilitates prolonged release of drugs. Currently, its lead candidate D-PLEX100 is in Phase 3 trials for preventing infections after colorectal surgeries.
Read more →PYPD▲ +14.3%on this news
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX 100 to 800 Patients with a Concurrent Private Placement of up to $41 Million 630 Patients Enrolled To Date; En
PolyPid Ltd. has received a positive recommendation from the Data Safety Monitoring Board (DSMB) to continue its Phase 3 SHIELD II trial for D-PLEX100, aimed at preventing surgical site infections. With 630 patients already enrolled, the trial is expected to conclude enrolling 800 patients shortly, allowing for the anticipated reporting of top-line results by mid-2025. Concurrently, the company is pursuing a private placement agreement to raise $41 million, which will help finance the trial and support other corporate objectives. The DSMB's positive feedback is viewed as an encouraging indicator of the drug's efficacy.
Read more →PYPDPolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
PolyPid Ltd. has announced a collaboration with ImmunoGenesis to develop innovative formulations aimed at enhancing cancer immunotherapy. Utilizing PolyPid's proprietary PLEX technology alongside ImmunoGenesis' STING agonist drug candidate, the partnership seeks to tackle challenges related to drug delivery in tumor treatments. This collaboration is part of PolyPid's broader strategy to enhance patient outcomes through innovative approaches in drug delivery methods.
Read more →PYPDPolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
PolyPid Ltd. has received a notification from Nasdaq regarding its non-compliance with the minimum stockholders' equity requirement, which is set at $2,500,000. As of September 30, 2024, the company reported stockholders' equity of approximately $2,158,000. PolyPid has 45 days to submit a compliance plan, with an opportunity for an extension of up to 180 days if successful. The notification does not immediately affect its Nasdaq listing. Additionally, upcoming interim analysis results from a trial may lead to additional funding if certain conditions are met.
Read more →PYPDPolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results Last Patient Enrolled for Planned Unblinded Interim Analysis in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 Unblinded Interim Analysis
PolyPid Ltd. has enrolled the last patient for the unblinded interim analysis in the ongoing SHIELD II Phase 3 trial of D-PLEX100, aimed at preventing surgical site infections. The company reported its financial results for Q3 2024 and expressed optimism over accelerated patient enrollment as all 60 planned centers became operational. Additionally, the firm anticipates topline results from the trial in the first quarter of 2025, highlighting their financial runway potentially extending into 2026. A conference call is scheduled for today to discuss these updates in detail.
Read more →PYPDPolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
PolyPid Ltd. announced its participation in the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, in New York. The company, which is focused on enhancing surgical outcomes, will engage in investor meetings at the event. PolyPid's lead product, D-PLEX100, is currently undergoing a Phase 3 clinical trial aimed at preventing surgical site infections following abdominal colorectal surgery. Additionally, the company is exploring OncoPLEX for treating solid tumors like glioblastoma in preclinical stages.
Read more →PYPDPolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
PolyPid Ltd. (Nasdaq: PYPD) announced that it will disclose its third quarter 2024 financial results and operational highlights on November 13, 2024. The report will be presented before the U.S. market opens, followed by a conference call at 8:30 AM Eastern Time to discuss the results further. The company focuses on improving surgical outcomes and is progressing with its lead product candidate, D-PLEX100, which is in Phase 3 clinical trials for preventing surgical site infections. Additionally, PolyPid is investigating the efficacy of OncoPLEX for solid tumors, starting with glioblastoma.
Read more →PYPD▼ -8.1%on this news
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
PolyPid Ltd. announced the publication of results from its Phase 3 SHIELD I trial of D-PLEX100, aimed at preventing surgical site infections in colorectal surgery. While the trial did not meet its primary endpoint, subgroup analyses indicated a significant 54% reduction in infections for patients with lengthy incisions. The company is optimistic about continued research, with the SHIELD II trial expected to offer further insights in Q1 2025. The trials unfold against a backdrop of changing surgical conditions due to the pandemic, which may have affected outcomes.
Read more →PYPDPolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim
PolyPid Ltd. has achieved a significant milestone by enrolling the last patient for the planned unblinded interim analysis in the SHIELD II Phase 3 trial of D-PLEX100, aimed at preventing surgical site infections in patients undergoing abdominal colorectal surgery. The unblinded interim analysis is scheduled for the current quarter, with preliminary results anticipated in early 2025. If positive efficacy is demonstrated, it could lead to an early trial conclusion and additional funding opportunities for the company. PolyPid is on track to announce full enrollment by the end of this year.
Read more →PYPDPolyPid to Participate in Three Upcoming Fall Investor Conferences
PolyPid Ltd. has announced its participation in three upcoming investor conferences, allowing management to engage with potential investors. Presentations will be available on-demand at the H.C. Wainwright Annual Global Investment Conference and the Lytham Partners Fall 2024 Investor Conference. The company also plans to take part in the Sidoti & Company Micro-Cap Virtual Conference in mid-November. PolyPid's lead product, D-PLEX100, is currently in Phase 3 trials targeting surgical site infections, and the company is exploring treatments for solid tumors.
Read more →PYPDPolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results Approximately 320 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical
PolyPid Ltd. provided a corporate update highlighting the ongoing SHIELD II Phase 3 trial of its product candidate D-PLEX100 for preventing surgical site infections after abdominal colorectal surgeries. With around 320 patients currently enrolled, the company expects to conduct an unblinded interim analysis after 400 patients complete their follow-up, aiming for top-line results in the first quarter of 2025. Additionally, the company successfully secured up to $14 million in financing, ensuring operational funding into 2025. PolyPid continues to focus on improving surgical outcomes using its proprietary drug delivery technology.
Read more →PYPDPOLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Condensed Consolidated Balance Sheets 1 - 2 Interim Condens
Polypid Ltd. reported its interim condensed consolidated financial statements for the period ending June 30, 2024, showcasing significant financial metrics. The total current assets rose to $9,778K, compared to $6,067K at the end of 2023. However, the company faced challenges with an increased net loss of $12,742K. Despite a notable uplift in shareholders' equity from negative balance, the operating loss also grew, indicating ongoing financial challenges.
Read more →PYPDPolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds Funding Extends Company's Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrant
PolyPid Ltd. has announced a private placement financing for up to $14 million to extend its cash runway into the second quarter of 2025. This funding will support the ongoing SHIELD II Phase 3 trial of its lead product candidate, D-PLEX100, aimed at preventing surgical site infections. The trial has enrolled over 300 patients, with key interim analysis expected in late 2024. The successful execution of this financing is essential for the company's operations leading up to the anticipated top-line results in early 2025.
Read more →PYPDPolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
PolyPid Ltd. announced it will report its second quarter 2024 financial results and operational highlights on August 14, 2024, before U.S. markets open. The company is actively advancing its lead product candidate, D-PLEX100, which is currently in Phase 3 clinical trials aimed at preventing surgical site infections. The conference call will take place at 8:30 AM Eastern Time to discuss these results and provide further business updates.
Read more →PYPDPolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial After a Reduction in Surgical Site Infection (SSI) Rates
PolyPid Ltd. held a Key Opinion Leader call to highlight the significant unmet medical need in preventing surgical site infections (SSIs) and provide updates on the Phase 3 SHIELD II trial for its lead product candidate D-PLEX100. The trial currently has about 250 patients enrolled out of a target of 600, with an interim analysis scheduled once around 400 patients complete their follow-up. The company emphasizes D-PLEX100's potential to improve surgical outcomes while addressing the resurgence of SSI rates post-COVID.
Read more →PYPDPolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial
PolyPid Ltd. announced it will host a virtual Key Opinion Leader event on June 17, 2024, discussing surgical site infections and updates on its D-PLEX100 Phase 3 trial. Featured speaker, Dr. Charles E. Edmiston, will highlight the clinical and economic impact of preventing these infections. The event aims to provide insights into patient enrollment in the ongoing SHIELD II trial. D-PLEX100 is designed to release antibiotics directly at the surgical site, potentially enhancing patient outcomes in abdominal colorectal surgeries.
Read more →PYPD▼ -11.3%on this news
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site
PolyPid Ltd. has provided a corporate update alongside first quarter 2024 financial results, revealing that over 200 patients have been enrolled in the SHIELD II Phase 3 trial for D-PLEX100, which aims to prevent abdominal colorectal surgical site infections. The company expects to conduct an interim analysis once approximately 400 patients have completed their follow-up, with top-line results anticipated in the second half of 2024. With approximately 50 centers now open for the trial and an enrollment pace of 1.5 patients per center monthly, PolyPid is well-positioned for further growth in this pivotal study.
Read more →PYPDPolyPid to Participate in Citizens JMP Life Sciences Conference
PolyPid Ltd. will participate in the Citizens JMP Life Sciences Conference in New York from May 13-14, 2024. At the conference, the management team will present and hold one-on-one investor meetings. PolyPid is known for its late-stage biopharma developments, especially its D-PLEX100 candidate, currently in Phase 3 trials for preventing surgical site infections. Additionally, they are exploring OncoPLEX for treating solid tumors, including glioblastoma.
Read more →PYPDPolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
PolyPid Ltd. has enrolled its 200th patient in the SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgeries. The trial is progressing well, with expectations to complete a planned unblinded interim analysis with approximately 400 patients by mid-2024. Top-line results are anticipated in the second half of 2024, and the company has secured financing to support its operations during this period, potentially receiving additional funds depending on interim results.
Read more →PYPDPolyPid Announces Enrollment of 200 th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Study Approximately Half Enrolled to the Planned
PolyPid Ltd. has announced that it has enrolled the 200th patient in its SHIELD II Phase 3 trial, which evaluates D-PLEX100 for preventing surgical site infections following abdominal colorectal surgery. The trial is now approximately one-third enrolled, with an expected interim analysis planned once 400 patients have completed their follow-up. The company anticipates top-line results in the second half of 2024 and recently secured $16 million in financing to support its operations. PolyPid’s D-PLEX100 aims to deliver prolonged antibiotic release at the surgical site to enhance patient outcomes.
Read more →PYPDPolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
PolyPid Ltd. announced that it will report its first quarter 2024 financial results on May 8, 2024, before U.S. market open. Alongside results, the company will host a conference call to discuss operational highlights and business updates. PolyPid is a late-stage biopharma firm focused on enhancing surgical outcomes through its proprietary drug delivery technology and is advancing its lead product candidate, D-PLEX100, through clinical trials.
Read more →PYPD▲ +8.7%on this news
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
PolyPid Ltd. has announced its participation in the Barclays 26th Annual Global Healthcare Conference, scheduled for March 12-14, 2024, in Miami Beach, FL. The company's management will engage in a fireside chat and hold one-on-one meetings with investors during the event. PolyPid is focused on improving surgical outcomes through its proprietary PLEX technology and is currently advancing its lead product candidate, D-PLEX100, in a Phase 3 clinical trial aimed at preventing surgical site infections.
Read more →PYPD▼ -8.2%on this news· ran to -23% by day 3
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorecta
PolyPid Ltd. has announced a corporate update along with its financial results for Q4 and full year 2023. The company reported that over 100 patients are now enrolled in its ongoing SHIELD II Phase 3 trial for D-PLEX100, which is focused on preventing surgical site infections. Financial results indicated a net loss of approximately $23.865 million for the year, although they successfully secured $16 million in financing to support their operations. Additionally, new preclinical data demonstrated OncoPLEX's effectiveness in reducing tumor volume and improving survival rates in animal models.
Read more →PYPDPolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
PolyPid Ltd. has announced the enrollment of the 100th patient in its SHIELD II Phase 3 trial for its product candidate D-PLEX100, aimed at preventing surgical site infections. The trial is actively enrolling in about 40 centers, with an unblinded interim analysis planned once around 400 patients complete their follow-ups, expected around mid-2024. The company recently secured $16 million in financing, which will help sustain operations through late Q3 2024, with the potential for an additional $19 million if warrants are exercised. Top-line results from the trial are anticipated in the second half of 2024.
Read more →PYPDPolyPid Announces Enrollment of the 100 th Patient in the Ongoing SHIELD II Phase 3 Trial Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their
PolyPid Ltd. has announced the enrollment of the 100th patient in its ongoing SHIELD II Phase 3 trial, aimed at preventing surgical site infections in patients undergoing abdominal colorectal surgery. Approximately 40 centers are currently open for recruitment. The company plans to conduct an unblinded interim analysis after 400 patients complete their 30-day follow-up, with expected top-line results in the second half of 2024. A recent financing round has provided $16 million to support the trial and there is potential for an additional $19 million if warrants are exercised.
Read more →PYPDPolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
PolyPid Ltd. has announced that it will report its financial results for the fourth quarter and full-year 2023 on February 14, 2024, before U.S. market opening. The company, which specializes in improving surgical outcomes, will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and updates on its business operations. The lead product D-PLEX100 is currently in a Phase 3 trial aimed at preventing surgical site infections, highlighting the company's active engagement in clinical advancements.
Read more →PYPD▼ -5.7%on this news
PolyPid Announces Private Placement for $16 Million in Gross Proceeds Financing Led by Leading U.S. Life Sciences-focused Investors
PolyPid Ltd. has announced a private placement financing agreement, raising $16.2 million from new and existing investors led by U.S. life sciences-focused firms. The financing will support the company's ongoing Phase 3 SHIELD II trial for its lead product D-PLEX100, which aims to prevent surgical site infections following colorectal surgery. Investors will receive shares priced at $4.81 each, along with warrants that could generate additional funding. The PIPE is expected to close on January 9, 2024, pending customary conditions.
Read more →PYPDPolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX 100 for the
PolyPid Ltd. announced a corporate update and financial results for Q3 2023. The SHIELD II Phase 3 trial for D-PLEX100, which aims to prevent surgical site infections, currently has 20 centers open, with plans to increase to 40 by the end of 2023. The company has successfully completed critical manufacturing milestones, including the production of process validation batches and a GMP audit. PolyPid is focused on supporting its employees amid the current situation in Israel, with no material impact on operations reported.
Read more →PYPD▲ +7.9%on this newsshared move
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal
PolyPid Ltd. has appointed Dr. Nurit Tweezer-Zaks to its Board of Directors effective November 6, 2023. This move follows the retirement of Anat Tsour Segal, who has served the company since its inception. Dr. Tweezer-Zaks is an established figure in the biopharmaceutical sector, with substantial experience in executive roles and medical practice. Her expertise is expected to bolster PolyPid's efforts as it approaches critical milestones for its lead product candidate, D-PLEX100, aimed at preventing surgical site infections.
Read more →PYPD▼ -5.8%on this newsshared move
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023
PolyPid Ltd. has announced that it will report its third quarter 2023 financial results on November 8, 2023. The company will hold a conference call at 8:30 AM Eastern Time to discuss these results and provide updates on its business operations. PolyPid specializes in improving surgical outcomes through its proprietary PLEX technology and is currently advancing its lead candidate, D-PLEX100, in a Phase 3 clinical trial aimed at preventing surgical site infections.
Read more →PYPDPolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
PolyPid Ltd. has announced that it has regained compliance with Nasdaq's minimum bid price rule. Following a review, Nasdaq confirmed that the company's ordinary shares maintained a closing bid price of $1.00 or higher for 11 consecutive business days. With this compliance, the prior deficiency matter is now closed. PolyPid continues to progress with its lead candidate D-PLEX100 in a Phase 3 trial targeting surgical site infections.
Read more →PYPDPolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
PolyPid Ltd. announced that clinical data for its product D-PLEX100 will be presented at the American College of Surgeons Clinical Congress 2023. The presentation, scheduled for October 23, 2023, will focus on the impact of D-PLEX100 on reducing infection rates in elective colorectal surgeries. The company aims to enhance surgical outcomes through its advanced drug delivery system. D-PLEX100 is currently in a Phase 3 clinical trial, while further research is underway on OncoPLEX for treating solid tumors, including glioblastoma.
Read more →PYPDPolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform
PolyPid Ltd. published positive preclinical results showing the safety profile of D-PLEX100 in juvenile animals, marking a significant step for this product aimed at preventing surgical site infections. The study, published in the International Journal of Toxicology, indicated no treatment-related adverse events over a nine-month evaluation period. These promising findings could pave the way for clinical evaluations in pediatric populations. D-PLEX100 is currently undergoing a Phase 3 trial, with top-line results anticipated in mid-2024.
Read more →PYPD▼ -9.2%on this news· ran to -27% by day 3
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
PolyPid Ltd. is set to present at the 2023 Cantor Fitzgerald Global Healthcare Conference from September 26-28, 2023, in New York City. The presentation is scheduled for September 28 at 8:00 AM Eastern Time. PolyPid aims to improve surgical outcomes through its proprietary PLEX technology, which supports controlled drug delivery. The company is currently focusing on its Phase 3 product candidate D-PLEX100, designed to prevent surgical site infections, and is also exploring its OncoPLEX treatment for glioblastoma in preclinical stages.
Read more →PYPD▼ -11.7%on this news· ran to -28% by day 3shared move
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
PolyPid Ltd. announced a successful GMP audit by the Israeli Ministry of Health for its manufacturing facility, critical for D-PLEX100 production. The audit found no major issues, allowing PolyPid to scale production for potential global commercialization of the antibiotic treatment designed to prevent surgical site infections. The company's CEO highlighted this audit as a significant milestone in the path toward D-PLEX100's launch. The product has also received Breakthrough Therapy Designation from the FDA and is currently undergoing Phase 3 clinical trials.
Read more →PYPD▲ +22.1%on this newsshared move
PolyPid Announces Reverse Share Split
PolyPid Ltd., a late-stage biopharma company, announced a reverse share split of its ordinary shares at a ratio of 1-for-30, effective September 21, 2023. This move follows shareholder approval obtained at an extraordinary general meeting on September 18, 2023, and aims to help the company meet Nasdaq's minimum bid price requirement of $1.00. Additionally, PolyPid is advancing its lead candidate, D-PLEX100, in Phase 3 clinical trials for preventing surgical site infections, while also preparing a preclinical study on its OncoPLEX product for solid tumors.
Read more →PYPD▼ -10%on this newsshared move
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀
PolyPid Ltd. has announced the successful completion of three process validation batches for D-PLEX100, a pivotal step towards filing New Drug Application (NDA) and Marketing Authorization Application (MAA). This achievement enhances the company's production capacity significantly, thanks to a recent facility expansion, thereby enabling full control over the manufacturing process. The lead product candidate, D-PLEX100, aims to prevent surgical site infections and is currently undergoing Phase 3 trials. With a promising future in regulatory submissions, the company reinforces its position as a fully-integrated biopharmaceutical entity.
Read more →PYPDpolypid Ltd. Notice of EXTRAORDINARY General Meeting of shareholders to be held on october 9, 2023 Notice is hereby given that an Extraordinary General Meeting of Shareholders (the " Meeting ") of PolyPid Ltd. (" PolyPid
PolyPid Ltd. has scheduled an Extraordinary General Meeting of Shareholders for October 9, 2023, at 2:00 p.m. Israel time. The meeting aims to discuss key resolutions as recommended by the board of directors. Shareholders recorded as of September 6, 2023, will be eligible to vote and can do so in person or by appointing a proxy. Proxy materials are being sent out to ensure that all shareholders can participate in the decision-making process.
Read more →PYPD▼ -11.7%on this news
POLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Condensed Consolidated Balance Sheets 2 - 3 Interim Condens
PolyPid Ltd. reported its interim condensed consolidated financial statements for June 30, 2023, showing total assets of $26,263, an increase from the prior period. Shareholders' equity rose to $8,347, signaling improved financial stability. However, the company also reported a significant net loss of $11,905. Despite efforts to reduce operating expenses, the overall financial performance indicates ongoing challenges as cash reserves decreased considerably.
Read more →PYPD▼ -11.7%on this news
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial E valuating D-PLEX 100 for the Prevention of Abdominal Colorectal S
PolyPid Ltd. has provided a corporate update and reported its financial results for the second quarter of 2023. The company has reached an agreement with the U.S. FDA on the design of its SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing abdominal colorectal surgical site infections. Enrollment in the trial has resumed, with 20 centers expected to open by the end of the current quarter. Despite positive developments, the company reported a net loss of $11.9 million and highlighted ongoing challenges related to high operating expenses and the current economic environment.
Read more →PYPDPolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
PolyPid Ltd. has announced that it will report its second quarter 2023 financial results and operational highlights on August 9, 2023, before U.S. markets open. The company aims to enhance surgical outcomes with its proprietary PLEX technology and is currently advancing its lead product candidate, D-PLEX100, in Phase 3 trials. Additionally, PolyPid is in preclinical stages for testing its OncoPLEX treatment for solid tumors, including glioblastoma.
Read more →PYPDPolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
PolyPid Ltd. announced the publication of a study demonstrating the effective antibacterial activity of its product D-PLEX100 against various bacteria, including resistant strains. This research supports its potential as a prophylactic treatment for surgical site infections (SSIs). D-PLEX100 utilizes innovative technology to maintain high localized antibiotic concentrations at surgical sites for extended periods. The product is currently under further evaluation in the SHIELD II Phase 3 clinical trial, with results expected in mid-2024.
Read more →PYPDPolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX for Prevention of Abdominal Colorectal Surgical Site Infections Company Recently Reached Agreement with FDA on Design of
PolyPid Ltd. has successfully recruited the first patient for its revised SHIELD II Phase 3 trial aimed at preventing abdominal colorectal surgical site infections with D-PLEX100. The FDA has accepted the new protocol for the trial, which will enroll approximately 550 patients over 12 months, with results anticipated in mid-2024. The trial aims to enhance patient outcomes by utilizing improved recruitment strategies and leveraging high-performing sites from an earlier study. An interim analysis will be conducted once around 400 patients complete their 30-day follow-ups.
Read more →PYPDPolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market PETACH TIKVA, Israel , June 5 , 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("
PolyPid Ltd. has announced an extension of 180 days to comply with Nasdaq's minimum bid price rule, allowing the company to transfer its listing to the Nasdaq Capital Market. This transfer is set to be effective from June 6, 2023, and the company hopes to regain compliance with a bid price of at least $1.00 per share. The move is a strategic effort to stabilize its share trading after previously receiving notification of non-compliance with Nasdaq rules. PolyPid's ongoing development efforts aim to improve surgical outcomes, advancing its lead product candidate through clinical trials.
Read more →PYPD▼ -6.3%on this news
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX for Prevention of Abdominal Colorectal Surgical Site Infections Recruitment to Resume Imminently Top-line Results Expected in Mid
PolyPid Ltd. announced that the FDA has agreed to the design of its SHIELD II Phase 3 trial evaluating D-PLEX100 for the prevention of surgical site infections in abdominal colorectal surgeries. Recruitment for the trial, which aims to enroll approximately 550 additional patients, is set to resume imminently. The total recruitment is expected to take about 12 months, with top-line results anticipated in mid-2024. This revised trial design is seen as an improvement based on learnings from the earlier SHIELD I trial, where positive data was generated.
Read more →PYPDPolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site
PolyPid Ltd. has provided a corporate update along with its financial results for Q1 2023, highlighting the submission of a revised protocol for its SHIELD II Phase 3 trial to the FDA. The company anticipates resuming patient recruitment shortly, bolstered by a strengthened financial position that extends its cash runway into late Q1 2024. Additionally, PolyPid has appointed Yossi BenAmram to its board of directors, bringing in valuable industry experience. Despite positive developments, the company reported a significant loss of over $6 million for the quarter.
Read more →PYPDARTICLES OF ASSOCIATION OF polypid Ltd. (as amended and restated on
The article provides the amended and restated Articles of Association for Polypid Ltd., a limited liability company governed by Israeli law. It outlines definitions of key terms, company objectives, procedures for general meetings, and the roles of the Board of Directors and Shareholders. The document serves as a formal framework for corporate governance and operational procedures within the company.
Read more →PYPDPolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
PolyPid Ltd. will release its first quarter 2023 financial results and operational highlights on May 10, 2023, before the U.S. financial markets open. A conference call and webcast is scheduled for 8:30 AM Eastern Time to discuss these results and the company's business updates. PolyPid is focused on enhancing surgical outcomes with its PLEX technology and is advancing its lead candidate, D-PLEX100, currently in Phase 3 clinical trials for preventing surgical site infections.
Read more →PYPDPolyPid to Participate in Upcoming Investor Conferences
PolyPid Ltd., a late-stage biopharma company, announced participation in several upcoming investor conferences, including the Aegis Capital Corp. and Sidoti & Company events. The management will also engage in one-on-one meetings with investors. PolyPid's lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing surgical site infections, and the company is exploring treatment options for solid tumors with its OncoPLEX technology. Their innovative PLEX technology is key to delivering drugs effectively over extended periods.
Read more →PYPD▲ +5%on this news
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance PETACH TIKVA, Israel , April 14 , 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma c
PolyPid Ltd. has received a notification from Nasdaq stating that it is not in compliance with the minimum stockholders' equity requirement, which mandates at least $10 million. As of the end of 2022, the company's stockholders' equity was reported at only $5,829,000. PolyPid has 45 days to submit a plan to regain compliance, during which time its shares will continue to trade. The company has raised about $11.4 million through recent financing efforts, which it believes may help restore compliance with Nasdaq requirements.
Read more →PYPD▲ +6.3%on this news
PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds
PolyPid Ltd. has successfully closed an underwritten public offering of ordinary shares, generating approximately $7.1 million and a concurrent private placement raising an additional $4.35 million. The proceeds are earmarked for ongoing clinical activities related to its lead product candidate, D-PLEX100. The company also restructured its loan with Kreos Capital, deferring over $3 million in repayments to align with expected results from a Phase 3 trial. This financial strategy provides PolyPid with the necessary resources to advance its development initiatives.
Read more →PYPD▼ -16.9%on this newsshared move
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
PolyPid Ltd. has announced the pricing of a public offering of 14,660,000 ordinary shares at $0.42 per share, expected to raise approximately $6.2 million. Concurrently, the company is conducting a private placement of $4.4 million involving pre-funded warrants. The proceeds from these offerings are intended to bolster ongoing clinical trials and general corporate activities. The expected closing date for both offerings is March 31, 2023, pending customary closing conditions.
Read more →PYPDPolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares
PolyPid Ltd. has announced a proposed underwritten public offering of its ordinary shares, intended to strengthen its financial resources for ongoing clinical activities and the development of its lead product candidate, D-PLEX100. The company will grant the underwriter a 30-day option to purchase an additional 15% of the shares offered. Importantly, the final terms of the offering will depend on market conditions and are not guaranteed, indicating potential uncertainty in the offering process.
Read more →PYPD▲ +5.3%on this news
PolyPid to Present at the Barclays Global Healthcare Conference
PolyPid Ltd. is scheduled to present at the Barclays Global Healthcare Conference in Miami from March 14-16, 2023. The company, which focuses on improving surgical outcomes, is currently advancing its lead product candidate D-PLEX100 into Phase 3 clinical trials aimed at preventing surgical site infections. Additionally, PolyPid is exploring the efficacy of another product, OncoPLEX, for treating solid tumors, including glioblastoma. This presentation offers an opportunity for investors to engage with the company during the conference.
Read more →PYPD▼ -12.8%on this news
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results Following Positive Communication with the FDA , Regulatory Pathway Clarified for D-PLEX 100 for Prevention of Abdominal Co
PolyPid Ltd. announced a corporate update along with its financial results for 2022, highlighting a positive communication from the FDA regarding the regulatory pathway for its drug D-PLEX100. The company expects to resume patient recruitment in Q2 2023 for the SHIELD II trial, which aims to prevent abdominal colorectal surgical site infections. The trial will enrich its patient base by incorporating approximately 550 additional patients, with top-line results anticipated in mid-2024. While the company remains optimistic, it reported a notable increase in net losses year-over-year.
Read more →PYPDPolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
PolyPid Ltd. plans to report its fourth quarter and full year 2022 financial results before the U.S. markets open on February 8, 2023. The announcement includes a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide operational updates. PolyPid focuses on improving surgical outcomes with its PLEX technology and has a lead product candidate, D-PLEX100, in Phase 3 trials.
Read more →PYPD▲ +10.2%on this news
PolyPid Provides Positive Regulatory Update for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interacti
PolyPid Ltd. announced a positive regulatory update for D-PLEX100, aimed at preventing surgical site infections during abdominal colorectal surgeries. The FDA recognized data from the SHIELD I Phase 3 study as potentially supportive for a future New Drug Application (NDA) submission. The agency suggested that ongoing SHIELD II trials may serve to complete the necessary clinical testing. PolyPid's CEO expressed confidence in the pathway for D-PLEX100's approval and mentioned plans for further discussions with European regulatory authorities.
Read more →PYPD▲ +7%on this news
PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery D-PLEX 100 Achieved in Phase 2 Tr
PolyPid announced the publication of a post-hoc analysis from its Phase 2 clinical trial for D-PLEX100, a treatment for preventing surgical site infections (SSIs) in abdominal surgery. The analysis, published in the American Journal of Surgery, showed a statistically significant reduction of SSIs by 53% when compared to standard care. This finding aligns with previous Phase 3 study results, further establishing D-PLEX100's potential efficacy, especially in patients with multiple preoperative risk factors. The treatment utilizes PolyPid's proprietary technology for a sustained antibiotic release, making it a promising option for high-risk surgical patients.
Read more →PYPDPolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery Meeting Sc
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery Scheduled for January 2023 Recently Provided FDA with Currently
Read more →PYPD▼ -6.2%on this newsshared move
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification PETACH TIKVA, Israel , December 9 , 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve su
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification TIKVA, Israel, December 9, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a written notice
Read more →PYPDPolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association
PETACH TIKVA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX100 will be highlighted in a podium presentat
Read more →PYPD▼ -9.6%on this news
PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results Company Intends to Meet with U.S. and EU Regulatory Authorities to Discuss Data from SHIELD I Phase 3 Study and Regulatory Pathway for D-
Provides Corporate Update and Reports Third Quarter 2022 Financial Results Company Intends to Meet with U.S. and EU Regulatory Authorities to Discuss Data from SHIELD I Phase 3 Study and Regulatory Pathway for D-PLEX100 in First Quarter of 2023 Implemented a Cost Reduction Plan
Read more →PYPDPolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022
PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results and operational highl
Read more →PYPDPolyPid Announces Cost Reduction Plan
Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss Regulatory Pathway for D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Surgery with U.S. and EU Regulatory Authorities in Q1
Read more →PYPDPolyPid Announces Cost Reduction Plan Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss Regulatory Pathway for D-PLEX 100 for Preventio
PolyPid Announces Cost Reduction Plan of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 Intends to Discuss Regulatory Pathway for D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Surgery with U.S. and EU Regulatory A
Read more →PYPDPolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery Centralized Procedure Allows for Submission of a Single Mar
PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery Centralized Procedure Allows for Submission of a Single Marketing Application to the European Medicines Agency that,
Read more →PYPDPolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
Intends to discuss the Clinical Outcomes and Next Steps for D-PLEX100 for the Prevention of SSIs in Abdominal Surgery with the FDA and the EU Regulatory Authorities in Q1 2023 PETACH TIKVA, Israel, Sept. 19, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the
Read more →PYPD▲ +58.3%on this news
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation PETACH TIKVA, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma co
Read more →PYPD▼ -73.5%on this news
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA Requested Pre-specif
Read more →PYPDPolyPid Announces Presentation at the 2022 Military Health System Research Symposium
Efficacy Data of D-PLEX100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation PETACH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma
Read more →PYPDPOLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 UNAUDITED INDEX Page Interim Condensed Consolidated Balance Sheets 2 - 3 Interim Condensed Consolidated Statements
AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Interim Condensed Consolidated Balance Sheets 2 - 3 Interim Condensed Consolidated Statements of Operations 4 Interim Condensed Consolidated Statements of Shareholders' Equity 5-6 Interim Condensed
Read more →PYPDPolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results Signed Exclusive Licensing Agreement for Commercialization of D-PLEX 100 in Europe for Potentially Over $110 Million in Upfront and Mile
Provides Corporate Update and Reports Second Quarter 2022 Financial Results TIKVA, Israel, August Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial resu
Read more →PYPD▲ +7.8%on this news
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe
PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales ADVANZ PHARMA to receive exclusive rights to commercialize D-PLEX100 for the prevention of surgical site infections in abdominal and cardiac surgeries in Europe,
Read more →PYPD▲ +7.8%on this news
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX 100 in Europe PolyPid to potentially receive over $110 million in upfront and milestone payments as wel
Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX100 in Europe to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales PHARMA to receive exclusive rights to commercialize D-PLEX100
Read more →PYPD▲ +6%on this news
PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022
PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2022 financial results and operational high
Read more →PYPD▲ +8.1%on this newsshared move
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation PETACH TIKVA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a l
Read more →PYPD▼ -5.3%on this news
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg PETACH TIKVA, Israel - July 5, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming
Read more →PYPD▲ +7.6%on this news
PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections
PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a key opinion leader (“KOL”) webinar on the cost of managing sur
Read more →PYPDPolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022
Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation PETACH TIKVA, Israel, June 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”)
Read more →PYPDPolyPid to Present at the JMP Securities 2022 Life Sciences Conference
PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which i
Read more →PYPDPolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects
Locally Administered Docetaxel Through Extended-Release Delivery via the Company’s PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-st
Read more →PYPD▲ +7.6%on this newsshared move
PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX 100 for Prevention of Surgical Site Infections in Abdominal Surgery Following Unblinded Interim Efficacy Analysis, Data Safety Monitoring Boa
PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum Numbe
Read more →PYPDPolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX 100 at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis Enr
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX100 at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis Patients, the Minimum Number of Patients Targeted for the S
Read more →PYPDPolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently
PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently Recruitment Progressing as Planned with Approximately 900
Read more →PYPDPolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022
PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational high
Read more →PYPDPolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine
Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma compan
Read more →PYPDPolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting
PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection So
Read more →PYPDPolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility Secured Loan facility with Kreos Capital Extends Company's Cash Runway into the Second Quarter of 2023
PolyPid Secures $15 Million Non-Dilutive Secured Secured Loan facility with Kreos Capital Extends Company's Cash Runway into the Second Quarter of 2023 PETACH TIKVA, Israel - April 6, 2022 - PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma comp
Read more →PYPDPolyPid to Deliver Poster Presentation at SAGES 2022
Presentation Evaluates Efficacy of D-PLEX100 in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery PETACH TIKVA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to impro
Read more →PYPD▲ +13.3%on this news
PolyPid Announces 750 th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX 100 in Abdominal Surgery Unblinded Interim Analysis Expected in the Second Quarter of 2022
PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX100 in Abdominal Surgery Unblinded Interim Analysis Expected in the Second PETACH TIKVA, Israel - March 2, 2022 - PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharm
Read more →PYPD▲ +13.3%on this news
PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery
PETACH TIKVA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, a
Read more →PYPD▲ +5.2%on this news· ran to +20% by day 3
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete the
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results PETACH TIKVA, Israel, February 9, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally a
Read more →PYPD▼ -5.5%on this news
PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022
PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, to
Read more →PYPDPolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board
Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “C
Read more →PYPD▲ +6.3%on this newsshared move
PolyPid Announces Planned CEO Transition Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022
PolyPid Announces Planned CEO Transition Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022 PETAH TIKVA, Israel, January 3, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focu
Read more →PYPD▲ +6.3%on this newsshared move
PolyPid Announces Planned CEO Transition
PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, tod
Read more →PYPDPolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery
PETAH TIKVA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics to improve surgical outcomes, announced to
Read more →PYPDPolyPid Announces 500 th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX 100 in Abdominal Surgery Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed b
PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX100 in Abdominal Surgery Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed by Top-Line Results Two Months Thereafter PETAH TIKVA, Isra
Read more →PYPDPolyPid Appoints New Oncology Advisory Board Member
PETAH TIKVA, Israel, Nov. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, tod
Read more →PYPDPolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Sur
Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery FDA Agreement that a Single Pivotal Phase 3 Study is Sufficient for Poten
Read more →PYPDPolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021
PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, tod
Read more →PYPDPolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference
PETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participati
Read more →PYPDPolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Signifi
Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged Survival Company Expe
Read more →PYPDtrue --12-31 Q2 2021 2021-06-30 6-K/A 0001611842 001-38428 PolyPid Ltd. 0001611842 2021-01-01 2021-06-30 0001611842 2021-06-30 0001611842 2020-12-31 0001611842 2020-01-01 2020-06-30 0001611842 2021-04-01 2021-06-30 00016
POLYPID LTD. AND ITS SUBSIDIARY INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS U.S. DOLLARS IN THOUSANDS Page Condensed Consolidated Balance Sheets 2 - 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Changes in Shareholders' Eq
Read more →PYPDPolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress
PETACH TIKVA, Israel, Aug. 17, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, announced today that its Co-Founder and Chief Scienti
Read more →PYPDPOLYPID LTD. AND ITS SUBSIDIARY INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Consolidated Balance Sheets 2 - 3 Condensed Consolidated St
LTD. AND ITS SUBSIDIARY CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DOLLARS IN THOUSANDS Page Condensed Consolidated Balance Sheets 2 - 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Changes in Shareholders' Equity 5 - 6 Condensed Con
Read more →PYPDPolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update Recruitment Progressing as Planned with Over 300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery F
Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update Recruitment Progressing as Planned with Over 300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Pot
Read more →PYPDPolyPid to Present at the Investor Summit Virtual Conference on August 18, 2021
PETACH TIKVA, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that Executive Vice President and Chief
Read more →PYPDPolyPid to Report Second Quarter 2021 Financial Results and Operational Highlights on August 11, 2021
PETAH TIKVA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its second quarter 2
Read more →PYPDPolyPid Strengthens Executive Team, Appointing Dr. Anthony Senagore as Senior Medical Director
PETAH TIKVA, Israel, July 12, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, today announced that it has appointed leading
Read more →PYPDThis presentation of PolyPid Ltd . (the "Company") contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws . Words such as "expects," "anticipa
2 This presentation of PolyPid Ltd . (the "Company") contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws . Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates"
Read more →PYPDPolyPid Presents today at The Raymond James Human Health Innovation Conference
PETAH TIKVA, Israel, June 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, announced that Dikla Czaczkes Akselbrad, Executive Vice
Read more →PYPDPolyPid to Present at Upcoming Healthcare Investor Conferences
PETAH TIKVA, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that members of its executive management
Read more →PYPDPolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX 100 Development Program FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX 100 for the Prevention of Surgical S
PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX100 Development Program FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal TIKVA, Israel, May 19, 2021 -
Read more →PYPDPolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery
PolyPid Ltd. Reports First Quarter 2021 Financial Provides Corporate Update Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks Manufactur
Read more →PYPDPolyPid to Report First Quarter 2021 Financial Results and Operational Highlights on May 12, 2021
PETAH TIKVA, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its first quarter 2
Read more →PYPDCompensation Policy PolyPid Ltd. (the "Company") Compensation Policy for Executive Officers and Directors Adopted
Compensation Policy for Executive Officers and Adopted June 18, 2020; Amended 1. Background 1 2. Compensation Objectives 1 3. Compensation policy 2 3.1. Officers' Compensation Package Components 2 3.2. Ratio between Fixed Compensation and Variable Compensation 2 3.3. Base Sa
Read more →PYPDpolypid Ltd. Notice of ANNUAL General Meeting of shareholders Notice is hereby given that an Annual General Meeting of Shareholders (the " Meeting ") of PolyPid Ltd. (" PolyPid " or the " Company ") will be held on
of ANNUAL General Meeting of shareholders Notice is hereby given that an Annual General Meeting of Shareholders (the "Meeting") of PolyPid Ltd. ("PolyPid" or the "Company") will be held on April 13, 2021 at 11:00 a.m. Israel time at the Company's office, located at 18 Hasivim
Read more →PYPDPolyPid Announces 100 th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX 100 for the Prevention of Post-Abdominal Surgery Incisional Infections Top-line Data Anticipated by Year End 2021 Enrollment Also Con
PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections Top-line Data Anticipated by Year End Enrollment Also Continues to Progress in Company's Second Phase 3 Clinical Trial,
Read more →PYPDPolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections
Top-line Data Anticipated by Year End 2021 Enrollment Also Continues to Progress in Company’s Second Phase 3 Clinical Trial, SHIELD II PETAH TIKVA, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve su
Read more →PYPDPolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results 100 Patients Enrolled into Phase 3 SHIELD I and SHIELD II Trials of D-PLEX 100 in Abdominal Surgery Recently Initiate
PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results TIKVA, Israel, February 10, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled,
Read more →PYPDPolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021
PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced th
Read more →PYPDPolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Syst
PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Stand
Read more →PYPDPolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX 100 for the Prevention of Post-Abdominal Surgery Incisional Infections Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress,
PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021 PE
Read more →PYPDPolyPid to Host Key Opinion Leader Call Discussing D-PLEX₁₀₀ and the Prevention of Surgical Site Infections
PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced t
Read more →PYPDPolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX 100 for the Prevention of Surgical Site Infections in Colorectal Surgery
Granted Breakthrough Therapy Designation from FDA for D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal TIKVA, Israel, November 24, 2020 - PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locall
Read more →PYPDPolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results Over 50% of planned 60 centers for ongoing Phase 3 SHIELD I trial of D-PLEX100 in abdominal surgery have received IRB approval Phase
Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results Over 50% of planned 60 centers for ongoing Phase 3 SHIELD I trial of D-PLEX100 in abdominal surgery have received IRB approval Phase 3 SHIELD II trial advanced; preparations underway to initiate by
Read more →PYPDPolyPid to Participate in Three Upcoming Investor Conferences
PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced th
Read more →PYPDPolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020
PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced th
Read more →PYPDPolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results Initiated Phase 3 SHIELD I Trial for D-PLEX 100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX 100 from FDA Pr
PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100 Positive Phase 2 Results of D-PLEX100 for Prevention of Surgical Site Infections
Read more →PYPDPolyPid to Report Second Quarter 2020 Financial Results and Operational Highlights on August 19, 2020
PETAH TIKVA, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced th
Read more →PYPDPolyPid granted Fast Track Designation from FDA for D-PLEX 100 for Prevention of Surgical Site Infections in Abdominal Surgery
granted Fast Track Designation from FDA for D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Surgery TIKVA, Israel, August 3, 2020 - PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally adminis
Read more →PYPDPolyPid to Present Phase 2 Results of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions
PETAH TIKVA, Israel, July 27, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced th
Read more →PYPDPolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Petah Tikva, Israel
PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Tikva, Israel - June 30, 2020 - PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, local
Read more →PYPDPolyPid Announces Positive Top-line Results from Phase 2 Clinical Trial of D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Surgery
D-PLEX100 Administration into the Surgical Site Led to Statistically Significant Reduction in Infections Compared to Standard of Care Alone Company Intends to Hold End of Phase 2 Meeting with FDA and Subsequently Submit an IND to Conduct a Phase 3 Clinical Trial in Abdominal Sur
Read more →Competitive Position
How PYPD ranks across every disease it competes inCompetitive Position is a premium feature
See how PYPD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial